by The global biosimilar monoclonal antibody market size was estimated to be around US$ 8.6 billion in 2022. It is projected to reach US$ 69 billion by 2032, indicating a CAGR of 23.2% from 2023 to 2032.
Key Points:
- In 2022, North America accounted for over 35% of the total revenue.
- The Asia-Pacific region is expected to experience the highest Compound Annual Growth Rate (CAGR) of 8.3% between 2023 and 2032.
- Within the “Type” category, the infliximab segment dominated the market with a 32% share in 2022.
- The adalimumab segment is projected to exhibit significant growth, with an anticipated CAGR of 24.7% from 2023 to 2032.
- In terms of “Indication,” the oncology segment secured a revenue share exceeding 44% in 2022.
- The autoimmune diseases segment is forecasted to register the fastest CAGR throughout the projected period.
- Among “End-users,” the hospital segment led the market in 2022, holding a substantial 49% market share.
- The “others” segment is expected to witness the fastest CAGR during the projected period.
Overview:
The Biosimilar Monoclonal Antibody Market refers to the competitive landscape and economic dynamics surrounding the production and distribution of biosimilar versions of monoclonal antibodies. Monoclonal antibodies are laboratory-produced molecules designed to mimic the immune system’s ability to fight off harmful pathogens. In the context of biosimilars, these are highly similar versions of existing monoclonal antibodies whose patents have expired.
Drivers:
This market is driven by the increasing demand for cost-effective alternatives to biologic drugs, as biosimilar monoclonal antibodies have the potential to offer comparable therapeutic effects at a lower cost. The overview of the Biosimilar Monoclonal Antibody Market typically includes insights into regulatory frameworks, research and development activities, market trends, and the competitive landscape among pharmaceutical companies
The market research report on the Biosimilar monoclonal antibody market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Biosimilar monoclonal antibody products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3400
Biosimilar Monoclonal Antibody Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 23.2% |
| Market Size in 2023 | USD 10.55 Billion |
| Market Size by 2032 | USD 69 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Type, By Indication, and By End User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Risk Analytics Market Size to Garner USD 79.24 Billion by 2032
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global Biosimilar monoclonal antibody market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Biosimilar monoclonal antibody market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Biosimilar monoclonal antibody products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the Biosimilar monoclonal antibody market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on Biosimilar monoclonal antibody market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Biosimilar monoclonal antibody market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Biosimilar Monoclonal Antibody Market Players
- Roche
- Novartis
- Pfizer
- Samsung Bioepis
- Amgen
- Mylan
- Teva Pharmaceutical Industries
- Biogen
- Celltrion
- Fresenius Kabi
- Sandoz
- Boehringer Ingelheim
- Merck
- Amneal Pharmaceuticals
- Biocon
Market Segmentations
By Type
- Adalimumab
- Bevacizumab
- Infliximab
- Rituximab
- Trastuzumab
- Others
By Indication
- Oncology
- Autoimmune diseases
- Others
By End User
- Hospitals
- Cancer treatment centers
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Biosimilar Monoclonal Antibody Market
5.1. COVID-19 Landscape: Biosimilar Monoclonal Antibody Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Biosimilar Monoclonal Antibody Market, By Type
8.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Type, 2023-2032
8.1.1 Adalimumab
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Bevacizumab
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Infliximab
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Rituximab
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. Trastuzumab
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Biosimilar Monoclonal Antibody Market, By Indication
9.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Indication, 2023-2032
9.1.1. Oncology
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Autoimmune diseases
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Biosimilar Monoclonal Antibody Market, By End User
10.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by End User, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Cancer treatment centers
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Biosimilar Monoclonal Antibody Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.1.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.1.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.1.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.1.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.1.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.1.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.5.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.5.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.5.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.5.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
Chapter 12. Company Profiles
12.1. Roche
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pfizer
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Samsung Bioepis
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Amgen
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Mylan
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Teva Pharmaceutical Industries
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Biogen
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Celltrion
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Fresenius Kabi
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
